Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT07358650

Clinical Study Evaluating the Safety and Performance of the MIST Device for Intraocular Pressure Reduction in Patients With Primary Open-Angle Glaucoma

Sponsor: Hexiris Inc

View on ClinicalTrials.gov

Summary

It is an interventional study for the treatment of Primary Open-Angle Glaucoma (POAG) using the Hexiris Microinvasive Scleral Trephine (MIST) system. This medical device includes a sclerectomy punch and injector assembly. It is a multicenter, open-label, non-randomized, single-arm study. Adults aged 40 years or more will be enrolled if the POAG is inadequately controlled by topical drug therapies. Only one eye per subject will be treated. The study will be performed on the first five patients in the operating room and the subsequent 20 patients will be treated under a slit-lamp in an aseptic environment (external patient clinic).Once treated with the MIST device, patients will return the next day, 1 week later and 1, 2, 3, 6, 9 and 12 months later. During these follow-up visits, the ophthalmologist will examine the eye and take measurements of the intraocular pressure.

Official title: A Multicenter, First-in-Human Clinical Study Evaluating the Safety and Performance of the MIST Device for Intraocular Pressure Reduction in Patients With Primary Open-Angle Glaucoma

Key Details

Gender

All

Age Range

40 Years - Any

Study Type

INTERVENTIONAL

Enrollment

Start Date

2026-01-15

Completion Date

2027-03-15

Last Updated

2026-01-22

Healthy Volunteers

Conditions

Primary Open Angle Glaucoma

Interventions

DEVICE

Hexiris Microinvasive Scleral Trephine (MIST)

The punch needle of the Hexiris MIST device was designed to be injected securely into the conjunctiva/sclera and remove a core of tissue, creating a channel in the sclera of the eye for reduction of IOP.

Inclusion Criteria: * Adults ≥ 40 years with uncontrolled mild to moderate POAG. * IOP ≥ 18 mmHg on ≥1 topical IOP-lowering medications. * Open angle on gonioscopy * Clear cornea and healthy ocular surface * Capable of giving informed consent, willingness to participate in the trial, and adhering to follow-up * Glaucomatous visual field loss in one or both eyes at presentation on any of these criteria: * Reproducible and reliable visual field defects on 2 consecutive fields * Mild, moderate or advanced disease on mean deviation according to Hodapp classification * Healthy, mobile conjunctiva in the target quadrant (superior bulbar region) * Best-corrected Snellen visual acuity of 20/100 or better * Visual field mean deviation no worse than -18.0 dB (without dense paracentral scotomas) * No anticipated need for other ocular surgeries (e.g., cataract) within 3 months of post-enrollment Exclusion Criteria: * Prior glaucoma filtering surgery (trabeculectomy, shunt or valve) in the treatment quadrant * Angle-closure, neovascular, uveitic, or traumatic glaucoma. * Eyes with conjunctival scarring, prior conjunctival surgery or other pathologies in the treatment quadrant * Eyes with scleral thinning, staphyloma, or structural abnormalities in the treatment quadrant * Uncontrolled IOP \> 35 mmHg at screening. * Active ocular infection or inflammation (e.g. blepharitis, conjunctivitis, keratitis, uveitis). * Active or recent (within 6 months) iris neovascularization in the treatment quadrant * Impaired episcleral venous drainage * Anterior chamber intraocular lens * Patients with uncontrolled bleeding disorders or those receiving anticoagulation therapy without appropriate perioperative management * Advanced glaucomatous optic neuropathy. * Fuchs endothelial dystrophy with clinical signs of endothelial decompensation. * Central corneal thickness (CCT) \> 600 μm. * Pathological myopia. * Patients unable to comply with postoperative follow-up or treatment instructions * Women who are (i) pregnant, (ii) nursing, (iii) planning a pregnancy and (iv) of childbearing potential not using a reliable method of contraception as outlined below are excluded: * Hormonal methods and the intrauterine device (IUD) must be in use at least 30 days prior to first study drug administration * Barrier methods must be in use at least 14 days prior to study drug administration * Your male partner vasectomy must be completed 3 months prior to first study drug administration or a sperm count of 0 should be confirmed.

Locations (5)

Eye Care Centre NB

Dieppe, New Brunswick, Canada

Miramichi EyeNB & Surgical Centres of Excellence

Miramichi, New Brunswick, Canada

Prism Eye Institute Inc.

Brampton, Ontario, Canada

Institut de l'oeil des Laurentides

Boisbriand, Quebec, Canada

Ophthalmology Clinic Bellevue

Montreal, Quebec, Canada